research Pharmacologic Inhibition of JAK-STAT Signaling Promotes Hair Growth
Blocking JAK-STAT signaling can lead to hair growth.
Search
for
Sort by
Research
90-120 / 1000+ results 
research Alopecia Areata: A Review of Diagnosis, Pathogenesis, and the Therapeutic Landscape
New treatments for alopecia areata show promise, but standardized guidelines are needed.
research Drug Armamentarium for Alopecia Areata
No cure exists for alopecia areata, and treatments are personalized.
research Safety and Efficacy of Tofacitinib in 97 Alopecia Areata Patients
Tofacitinib is an effective and safe treatment for alopecia areata.
research Clinical Outcomes for Uptitration of Baricitinib Therapy in Patients With Severe Alopecia Areata
Increasing the dose of baricitinib to 4 mg helps more patients with severe alopecia areata regrow hair.
research Integrated Safety Analysis of Baricitinib in Adults With Severe Alopecia Areata From Two Randomized Clinical Trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research Outcomes of Down-Titration in Patients with Severe Scalp Alopecia Areata Treated with Baricitinib 4 Mg: Week 104 Data from BRAVE-AA2
Reducing the dose of Baricitinib to 2mg led to a loss of hair regrowth benefits in nearly half of the patients by Week-104.
research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata
Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
research JAK Inhibitor Baricitinib in the Treatment of Oral Lichen Planus: A Case Report
Baricitinib may effectively treat oral lichen planus.
research Adverse Events in Patients Treated With Jak-Inhibitors for Alopecia Areata: A Systematic Review
JAK-inhibitors for alopecia areata are generally safe with mostly mild side effects and a low rate of treatment withdrawal.
research Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study
Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.
research Induction of T Cell Exhaustion by JAK1/3 Inhibition in the Treatment of Alopecia Areata
Ifidancitinib, a JAK inhibitor, effectively regrows hair in mice with alopecia by tiring out harmful T cells.
research Rapidly Progressive Alopecia Areata Totalis in a COVID-19 Patient, Unresponsive to Tofacitinib
A COVID-19 patient with severe hair loss did not improve with hair loss medication after stopping and restarting it due to the infection.
research Ruxolitinib for the Treatment of Severe Alopecia Areata
Ruxolitinib can help regrow hair in severe alopecia areata.
research Successful Hair Regrowth in a Korean Patient with Alopecia Universalis Following Tofacitinib Treatment
A Korean woman with complete hair loss regrew her hair after taking tofacitinib, with no side effects.
research An Excellent Response to Tofacitinib in a Brazilian Adolescent Patient with Alopecia Areata: A Case Report and Review of the Literature
A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.
research Upadacitinib Efficacy for the Treatment of Concomitant Psoriasis and Alopecia Areata
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
research An Open-Label Pilot Study to Evaluate the Efficacy of Tofacitinib in Moderate to Severe Patch-Type Alopecia Areata, Totalis, and Universalis
Tofacitinib may help treat severe hair loss, but more research is needed.
research Alopecia Areata and Alopecia Areata Incognita
Alopecia Areata is an autoimmune hair loss condition, with various treatments showing mixed effectiveness and no guaranteed cure.
research Balance of Tofacitinib Efficacy and Disease Flare in the Treatment of Alopecia Universalis: A Case Report and Review of the Literature
Tofacitinib can temporarily improve hair growth in alopecia universalis, but its effectiveness may decrease over time.
research Molecular Correlation With Clinical Outcomes in an Open Label Clinical Trial of Oral Tofacitinib in Patients With Alopecia Areata
Tofacitinib helped most patients with alopecia areata regrow hair and changes in immune cells were linked to the treatment's effectiveness.
research Clinical and Genetic Aspects of Alopecia Areata: A Cutting Edge Review
Hair loss from Alopecia Areata is caused by both genes and environment, with several treatments available but challenges in cost and relapse remain.
research Case Report: Alopecia Areata Universalis Successfully Treated with Baricitinib
Baricitinib successfully treated severe hair loss.
research Excellent Response to Tofacitinib Treatment in a Patient with Alopecia Universalis
A patient with complete hair loss regrew all her hair using tofacitinib.
research Treatment of Crohn's Disease and Concomitant Alopecia Areata With Tofacitinib
Tofacitinib successfully treated hair loss in a Crohn's disease patient who previously used adalimumab.
research Efficacy of Tofacitinib in the Treatment of Universal Alopecia Areata and Primary Sjögren Syndrome
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
research Alopecia in General Medicine
The document concludes that diagnosing and treating hair loss is complex and requires understanding its psychological effects and underlying causes, while also calling for more research and new treatments.
research Translational Positioning of Janus Kinase (JAK) Inhibitors in Alopecia Areata
JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.
research The Efficacy and Safety of JAK Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis of Prospective Studies
Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.